As of early 2026, the surgical field in the United States has reached a critical turning point where biological integration is now a standard requirement for complex procedures. According to the latest US Market analysis, the domestic industry is valued at approximately $5.24 billion, reflecting a robust healthcare infrastructure that increasingly relies on advanced hemostats and tissue...